A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry

Monoclonal antibodies (mAbs) are key components in several therapies for cancer and inflammatory diseases but current knowledge of their clinical pharmacokinetics and distribution in human tissues remains incomplete. Consequently, optimal dosing and scheduling in clinics are affected. With sequentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Morschhauser, F., Dekyndt, B., Baillet, C., Barthélémy, C., Malek, E., Fulcrand, J., Bigot, P., Huglo, D., Décaudin, B., Simon, N., Odou, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173718/
https://www.ncbi.nlm.nih.gov/pubmed/30291297
http://dx.doi.org/10.1038/s41598-018-33160-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173718/
https://www.ncbi.nlm.nih.gov/pubmed/30291297
http://dx.doi.org/10.1038/s41598-018-33160-0

Ejemplares similares